Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup-Reference-Cited by-同舟云学术

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

Published:2014-08-21 Issue:8 Volume:124 Page:1312-1319
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hospital Marie-Anne¹,Prebet Thomas²,Bertoli Sarah³,Thomas Xavier⁴,Tavernier Emmanuelle⁵,Braun Thorsten⁶,Pautas Cécile⁷,Perrot Aurore⁸,Lioure Bruno⁹,Rousselot Philippe¹⁰,Tamburini Jérôme¹¹,Cluzeau Thomas¹²,Konopacki Johanna¹³,Randriamalala Edouard¹⁴,Berthon Céline¹⁵,Gourin Marie-Pierre¹⁶,Recher Christian³,Cahn Jean-Yves¹⁷,Ifrah Norbert¹⁸,Dombret Hervé¹,Boissel Nicolas¹

Affiliation:

1. Department of Hematology, EA-3518, Paris 7 University, Hôpital Saint-Louis, Paris, France;

2. Department of Hematology, Institut Paoli-Calmettes, Marseille, France;

3. Department of Hematology, Centre Hospitalier Universitaire Purpan, Toulouse, France;

4. Department of Hematology, Hôpital Edouard Herriot, Lyon, France;

5. Department of Hematology, Institut de Cancérologie de la Loire, Saint Etienne, France;

6. Department of Hematology, Hôpital Avicenne, Bobigny, France;

7. Department of Hematology, Hôpital Henri Mondor, Créteil, France;

8. Department of Hematology, Hôpital de Brabois, Nancy, France;

9. Department of Hematology, Hôpital Hautepierre, Strasbourg, France;

10. Department of Hematology, Centre Hospitalier de Versailles, Versailles, France;

11. Department of Hematology, Hôpital Cochin, Paris, France;

12. Department of Hematology, Centre Hospitalier Universitaire Nice, Nice, France;

13. Department of Hematology, Hôpital d’Instruction des Armées Percy, Clamart, France;

14. Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;

15. Department of Hematology, Hôpital Claude Huriez, Lille, France;

16. Department of Hematology, Centre Hospitalier Universitaire Limoges, Limoges, France;

17. Department of Hematology, Clinique Universitaire d'Hématologie, Centre Hospitalier Universitaire Michallon, Grenoble, France; and

18. Department of Hematology, Centre Hospitalier Universitaire et INSERM U892-Centre National de la Recherche Scientifique Unité Mixte de Recherche 6299, Angers, France

Abstract

Key Points GO before transplant improves outcome of CBF-AML patients in first relapse.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/8/1312/1382392/1312.pdf

Reference31 articles.

1. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.;Shigesada;Oncogene,2004

2. The 8;21 translocation in leukemogenesis.;Peterson;Oncogene,2004

3. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.;Döhner;Blood,2010

4. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial.;Grimwade;Blood,1998

5. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.;Bloomfield;Cancer Res,1998

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study;Annals of Hematology;2024-01-26

2. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment;Blood Reviews;2023-11

3. Gemtuzumab Ozogamicin Monotherapy Is a Well-tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature;Journal of Pediatric Hematology/Oncology;2023-10-09

4. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo;Leukemia;2023-07-18

5. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16);BMC Cancer;2023-05-25